Presenting on today's call will be X4's Chief Executive Officer Doctor. Paula Ragan Ragan and Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open the call to your questions and we'll be joined by Chief Commercial Officer, Mark Baldry, and Chief Medical Officer, Doctor. Christophe Arbett Engels. As a reminder, on today's call, the company will be making forward looking statements regarding regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's most recent filings with the SEC including last year's Form 10 ks and this past quarter's Form 10 Q. Which is expected to be filed after market close today. Please note that the X4 investor deck was updated this morning on the company website to include slides detailing some of the data analyses mentioned in this morning's press release and on this call today. I'd now like to turn the call over to X4's President and CEO, Doctor. Paula Ragan. Paula, Thank you, Dan, and thanks to all of you for joining us this morning. The first quarter of twenty twenty five was an extremely productive and value building period for X4 with clinical trial advancement in chronic neutropenia, continued progress the commercialization of ZOLREMD for WHIM Syndrome in The US, and our achievement of several significant milestones, towards expanding the global potential of MAVERICK's IV for patients.

Let's begin with MAVERICK's IV in chronic neutropenia, or CN, As you know, having successfully developed MAVERICK's IV branded ZOLUMDI for patients with WHIM Syndrome in The U. S, we are now also developing MAVERICK S4 for the larger indication of chronic neutropenia. There are currently about fifty thousand people diagnosed with some form of CN in The US, based on retrospective ICD-ten code analyses. Of those currently diagnosed with primary CN, we estimate that approximately fifteen thousand individuals or about thirty to forty percent have remaining health challenges and continue to experience low absolute neutrophil counts, or ANCs, and recurrent infections despite available standard of care. We define this as the high unmet need CN patient population And it is with this population in mind that we are launching our ongoing FORWARD trial. A global pivotal phase three clinical trial evaluating the safety and efficacy of once daily oral Mavorixafor in people with certain chronic neutropenic conditions. Including primary autoimmune idiopathic, and congenital neutropenia, and who are experiencing recurrent and or serious infections. As we reported on our last call, we're now screening and enrolling participants in over 20 countries with more than ninety percent of our target global trial sites being activated.

Additionally, we've now finalized the trial design based on the feedback also discussed previously from both the FDA and EMA to focus on those with the highest unmet needs. A population that matches up well with Maverick's first targeted commercial CN patient population. The trial is enrolling with those with moderate to severe CN or ANC below 1,000 cells per microliter and experiencing two or more infections over the past twelve months. We also finalized the ANC response endpoint, The definition of ANC response is now uniform across all participants and is defined as an increase in ANC greater than 500 cells per microliter versus baseline ANC and occurring at 50% or more of the time points evaluated in the trial. The trial seeks to demonstrate statistically significant increases in ANC response, and corresponding decreases in annualized infection rates between those on MAVERICK-four versus placebo. To date, the demographics of the enrolled population are balanced and representative of the target commercial CN patient populations, and baseline ANCs and historical infection rates are consistent with this high unmet need population. We recently completed some additional data that further increased our confidence the success of the FORWARD trial. Individual patient data from both the MAVERICK-four Phase III four WHIM trial and the completed Phase two CN trial have now been analyzed applying this just mentioned FORWARD trial ANSI response criteria.

The full details of these analyses can be found in the updated investor deck that is on the front page of the Investors section of our website. In summary, we created what we're calling heat maps. Which detail individual ANC responses across all trial participants at all of the assessed time points. Specifically, the four WHIM Phase III heat map provides a benchmark for ANC responses that translated into a 60% reduction annualized infection rate. When comparing MAVERICK's IV treatment to placebo. The CN Phase II heat map demonstrates the impact of MAVERICK's four on durable increases in ANC across those with idiopathic cyclic, and congenital chronic neutropenia. ANC outcomes in the CN Phase II trial look similar to ANC responses seen in the MADRIX-four arm of the four WHIM trial. When taken together, these heat maps analyses provide evidence supporting the potential success of the CN Phase III trial where we believe that the expected ANC responses resulting from maverick support treatment will correspond to a significant decrease in annualized infection rates. We also continue to believe that the forward trial is rigorously designed and powered to demonstrate the impact of MAVERICK's for NCM. The trial is powered at greater than 95% to assess the ANC response endpoint.

And the 150 participant sample size independently supports robust powering at greater than ninety percent for the infection rate revolves. As of today, we continue to anticipate full enrollment in the trial in the third or fourth quarter of twenty twenty five, which would enable disclosure of top line data in the second half of twenty twenty six. Lastly, on the CN front, we have good news from the U. S. Patent Office. We received a notice of allowance on our application, which claims include the use of MAVERICK's IV in treating severe chronic idiopathic and autoimmune neutropenia in patients without a CXCR4 genetic variant. The patent is expected to expire in The US in February. Similar patent applications are pending in Europe, China, Japan, and Canada. To conclude, we remain confident that we'll be able to deliver on our upcoming milestones in CN, that will have a long term patent protection in the indication and that the value proposition for Maverick's four and CN represent a 1,000,000,000 to $2,000,000,000 opportunity in The US alone. With that, let's turn now to our progress with MAVERICK's four in WHIM Syndrome. At the March, cumulative sales of ZOLREMD reached 3,500,000.0 since our mid May launch last year.

This quarter's sales were slightly lower than those reported in the fourth quarter because of the fluctuations in the timing of inventory resupply, which causes some lumpiness to sales. This is typical with markets anchored in small patient populations and early in launch. We do expect this to even out over time with the increasing demand that we're already seeing. We are currently in the thick of conference season and continue to have fruitful engagements with all of our targeted top tier immunologists and hematologists increasing the visibility of WHIM syndrome. And we're seeing success in our educational efforts that support HCPs in finding limb patients. With new patients now representing approximately forty percent of our current ZOLREMDI treated population, at the end of the first quarter. In addition, we're just about to kick off our WHIM patient ambassador program and hope these efforts will continue to build demand for ZIL REMVY in The U. S. As we discussed on our last call, we made significant progress in our efforts to expand the potential global reach of MAVERICK score in WHIM during the first quarter. In January, we announced that our submitted MAA was accepted by European regulatory authorities for review, With a typical twelve to fifteen month review process, we anticipate potential approval from the EMA as early as the first quarter of twenty twenty six.

We also announced the completion of two international partnerships in the first quarter, The first with Norgene, a leading European specialty pharmaceutical company to commercialize Mavericks for in Europe, Australia, New Zealand. Noregene will be launching Maverick's support for the women to key in the EU should we receive approval there next year and we are working closely with them to ready for that possibility. The second partnership is with TABA RARE, another specialty pharmaceutical company to commercialize ZOL Remedy in The Middle East and North Africa region. Following any approvals there. The MENA region does have a compassionate use program that allows physicians to prescribe drugs approved in other countries to local patients with no other treatment options, we'll keep you updated on our progress there. Lastly, we're continuing to advance the understanding of WHIM syndrome as well as the impact of MAVERICK's four on the disease. We had two abstracts accepted for publication at the annual meeting of the Clinical Immunology Society, or CIS, which starts today. From the four WHIM Phase III Open Label Extension, or OLE, we'll be presenting two year data that demonstrate a market clinical improvement in wart severity as assessed by a standard measurement.

The clinical global impression of severity across 70 defined wart areas. We're also presenting results from the first ever survey looking into infection burden in WHIM patients, 20 WHIM patients provided responses None were on zolrembi at the time. The survey revealed that sixty percent of those 18 years and seventy three percent of those 18 or over reported experiencing at least one infection in the previous three months. With twenty five percent requiring overnight hospitalizations due to infection the study concludes that, quote, the frequency and severity of infections requiring medical care and hospitalizations underscores the urgency to proactively treat patients with WHIM Syndrome. Needless to say, we're very proud to be able to have developed this first approved therapy for WHIM in The US and look forward to commercial updates and continued global advancements milestones, the coming quarters. I'll now turn it over to Adam to run through our financials. Adam? Thanks, Paula. As we disclosed in the press release this morning, we ended the first quarter of twenty twenty five with just under $90,000,000 in cash and cash equivalents. We continue to believe that we have sufficient funds to support company operations into the first half of twenty twenty six.

We reported net ZOLE Remedy revenues of just under $1,000,000 for the first quarter of twenty twenty five, As Paula mentioned, this brings our cumulative total sales since our May 2024 launch to about $3,500,000 Our R and D expenditures totaled $18,500,000 for the first quarter and our SG and A expenses were $15,000,000 for the first quarter. And finally, had a small amount of net income in the first quarter due to the recognition of $28,000,000 in license and other revenue from our partnership with Norgeene and a gain of $10,800,000 on our outstanding Class C warrants, which are measured at fair value each quarter. We also note that our one for-thirty reverse stock split became effective on Monday following shareholder and Board approval, and we believe this should cure our current deficiency with the NASDAQ listing rules. Lastly, we have now completed the majority of the actions we laid out during our announced strategic restructuring in February. We continue to expect that these efforts will decrease our spending by about 30,000,000 to $35,000,000 annually. We'll now open the call up to your questions. Operator?

Thank you. Once again, to ask a question, please press and one on your telephone keypad. We'll take our first question. From Ted Sansons with Piper Sandler. Please go ahead.

Great. Thank you very much. Can you give us a sense if you have any visibility into the types of patients that are being enrolled in [indiscernible] Expected that you were enrolled [indiscernible] And then I'll follow-up on So of course, we mentioned that we're very pleased with the overall profile, but So we have the in itself is very has very specific criteria. And we have the profile of the patients that we are having is really is really good so far and we're tracking this What I can share anecdotally having met with some of the PIs and meeting with some others is that lot of those PIs would love to include many more patients than the patients we have into the study and they often have all these patients waiting, they cannot change their treatment just to include them in the study. Obviously, but there's a clear demand here and interest in trying to bring as many patients as possible into the study. Great. Thank you very much.

Sure. Okay. Maybe Mark just has one more comment there.

Yes. Ted, I was just going say, we're continuing to build our insights into 95 US physicians who treat chronic neutropenia and what we're finding is the caseloads of patients that these physicians have are much higher than in WHIM. So in WHIM, it's a very fragmented model. In chronic neutropenia, it's much more concentrated, much more defined because there are distinct definitive ICD-ten diagnosis codes we can clearly see where these patients are and the unmet need in this refractory population.

So I think just to quickly summarize, you've had very sick patients being enrolled in the study to enrich for success on the infection endpoint, higher demand both locally in the trial because they'd love to get their patients in the trial, but course we can't accept everybody in end markets seeing that pull through in terms of the higher case flows through our market research.

Great. That's very helpful. Thank you.

Thank you, Ted.

Thank you. Our next question comes from RK with H. C. Wainwright. Please go ahead.

Thank you.

Good morning, Paula and Adam.

A couple of quick questions. You know, in in the the patient the amount of patients that you said who are being diagnosed with CN, which is, like, fifty thousand people, and out of that fifteen thousand are the ones that seem to be having the high unmet need These numbers, are they just US or are they worldwide?

They're just US, okay. Yes. We did an ICD-ten code analysis and The US claims data.

Okay. Okay, perfect. And then from your you know, comments to Ted's question, you know, you were stating that only very sick patients are being enrolled into the study. So I'm thinking about the label. When what sort of [indiscernible] the target population would you be looking at on the label? Is it the very sick population, or is that is that beyond that? How do we define that population? [indiscernible] Christophe here. Because we do have already also from this [indiscernible] experience with also other population, even if we're if the Phase III study includes moderate and severe patients, we are going to build a case for the label for the entire CN population, and we do have already data to support this. Including from the WIM study etcetera. So we are anticipating a broad label but obviously this will be a matter of discussions with the FDA at the time when it comes.

Our case is to kind of crosswalk obviously into the value proposition. We are focusing on treating patients who are basically refractory with severe recurrent infections. That is who needs remaining treatments, And certainly when we go into the payer systems across the world, we want to be focusing on that basically that high unmet need with little to no options. To demonstrate the value proposition of golrembi for [indiscernible] So there's a good connection between the severity of the disease, the trial design, and the ultimate value that we think we can bring to patients.

Okay, one last question, I'm sorry. The the the transaction with the or the the agreement with Noregene that you currently have for commercialization in Europe and Australia. Does that go by indication, or does that go by Mavorixafor, period?

Yeah, thanks, Arpit. So, it covers WHIM and CN. So it's licensed to the asset across both indications. Obviously, first will be when commercially followed by CN.

Okay, perfect.

Thanks. Thanks for taking my questions.

Thank you, RK.

Thank you. And as a reminder, it is will move next with Steven Wiley with Stifel. Please go ahead. Your line is open.

Yes, good morning. Thanks for taking the questions.

I guess with the understanding that the commercial history here in WIM is a bit abbreviated thus far, Is there anything that you can say about just patient persistency and compliance that you're seeing?

Sure, morning.

Steve.

Mark here.

Yeah, I mean, think what we're pleased with is that although we're not being down any actual numbers, we're pleased to see that compliance and adherence rates are actually higher you would expect with a daily oral medication. And I think that speaks to the unmet need here and that these patients and physicians understand that this disease needs treatment, and ZOLENBI is the solution. If it's taken appropriately. We're now actually spending a lot of time beginning to educate patients and the patient community and in fact, to announce that we just launched a new website yesterday.

In fact, I encourage you to open your browser of choice and type in wimsyndrome.com and you'll see our new patient education website that features WHIM patients telling their stories and also provides a lot of resources to help them on their journey with WIM and with Zohrabi.

Okay. And are most patients getting a thirty day supply, or are some patients getting three months worth of drug via a single script?

The majority of patients are on the higher dose. Of course, it's weight based. So, if the patient is of a lighter weight, they get a lighter dose.

I guess the question was, if the prescription unit size that most patients are getting, is it a month supply or are some patients getting three months worth of drug? With a single prescription? It's a month supply at this stage.

Okay.

And then understanding that the FORWARD trial is is blinded, But can you just remind us what your assumption was around patient dropout and if there's any data that you're able to see on a blinded basis that would suggest that that assumption is holding up in the clinical trial.

Yeah, so, Steve, what we're targeting as we shared, is about one hundred and fifty patients enrolled. And all of that has some degree of assumptions of either dropout or screening failures, etcetera. So we're building that funnel I think more importantly, what we can see with the RE enrolled subjects is really about their profile. Like, are we in good shape on the one hundred and fifty, because that sort of sets our clock. The answer there is definitely yes. We're seeing the right blend of idiopathic autoimmune and congenital and balanced nicely. And then of course, this is all blinded, but we're seeing the event rates you would want to see early in the study to confirm our assumptions. So in terms of powering that one hundred and fifty is built and suspenders for the co primary endpoint. So I think that could give some confidence. In terms of the rate so many ins and outs. What we can say is certainly based on everything we're seeing, we're on track for that Q3, Q4 enrollment.

Okay, very helpful. Thanks for taking the questions.

Thank you, Steve.

Thank you. And we show no further questions at this time. I will turn the call back to Paula Regan for closing remarks.

Well, you very much for joining us today. Happy to follow-up offline with any other questions, and wish you all an excellent rest of your day. Thank you.

And this does conclude today's program. You for your participation. You may disconnect at any time.